The discovery and validation of new drug targets in cancer.
Advances in our understanding of the signal transduction pathways involved in cellular growth control have provided several new strategies for cancer therapy. Recent advances now make it possible to develop selective inhibitors targeting genomic instability, the growth, survival, and invasion of the tumor, and its nourishment through the growth of new blood vessels.
Courtneidge
S A
SA
SUGEN Inc. 230 East Grand Avenue South San Francisco CA 94080 USA. sara-courteneidge@sugen.com.
Plowman
G D
GD
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000627:therapeutic use / Q000633:toxicity; D017209:Apoptosis; D002455:Cell Division; D002470:Cell Survival; D015195:Drug Design; D006801:Humans; D009361:Neoplasm Invasiveness; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009389:Neovascularization, Pathologic
D000970:Antineoplastic Agents